Minaris Regenerative Medicine has announced a total investment of $64.5m to significantly expand its facilities in Europe and Asia.
The European facility will be built in the proximity of the existing site in Ottobrunn near Munich, Germany with a total investment of $40.7m.
The facility will operate according to GMP standards (FDA and EMA) and be dedicated to clinical and commercial manufacturing as well as development services for cell and gene therapies. The multi-storey building with a total of 6,650 sqm will provide the company additional cleanrooms, quality control laboratories, warehousing, cryo-storage and office space.
It will have a modular design with the possibilities to go from single room to ball room design and to flexibly change between grade B and grade C configuration. The facility is expected to be operational early 2023 and will allow for additional expansion of cleanrooms according to client demand and specifications, thus more than tripling the current cleanroom capacity.
“We are very pleased to expand our capacity to support the growing demand of clients who continue to care for an increasing number of patients in the future”, said Dusan Kosijer, Managing Director of Minaris Regenerative Medicine GmbH.
A facility will also be established adjacent to the existing facility in Yokohama, Japan allowing for an additional 4,000 sqm which will double the capacity for commercial manufacturing of regenerative medicine. This facility is scheduled to start operations in October 2022. The investment of $23.8m is part of a strategy to establish a centre for cancer immunotherapy and somatic stem cells.
“Our investment in the facility expansions of all our three regional sites confirms our commitment to contract development and manufacturing for the cell and gene therapy industry”, commented Kazuchika Furuishi, PhD, Corporate Officer and General Manager, Regenerative Medicine Business Sector of Showa Denko Materials.